一、会议召开和出席情况 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 （一）会议召开情况 5.会议主持人：赵一霖 6.召开情况合法、合规、合章程性说明： 第三届监事会第十三次会议决议公告 山西大禹生物工程股份有限公司 证券代码：871970 证券简称：大禹生物 公告编号：2024-050 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 3.回避表决情况 本议案不涉及关联交易事项，无需回避表决。 本议案无需提交股东大会审议。 本次会议的召开符合《中华人民共和国公司法》、《公司章程》和《监事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司<2024 年第三季度报告>》议案 1.议案内容： 具体内容详见公司于 2024 年 10 月 28 日在北京证券交易所信息披露平台 （www.bse.cn）上披露的《2024 年第三季度报告》（公告编号：2024-051）。 1.会议召开时间： ...

Financial Performance - Operating revenue for the first nine months of 2024 was CNY 89,245,304.80, down 22.50% year-over-year[3]. - Net profit attributable to shareholders for the first nine months of 2024 was a loss of CNY 16,117,302.93, representing a 156.06% increase in loss compared to the same period last year[3]. - The company recorded a net loss of CNY 16,117,302.93 for the current year, primarily due to decreased operating revenue and increased management costs[5]. - Total operating revenue for the first nine months of 2024 was ¥89,245,304.80, a decrease of 22.5% compared to ¥115,156,370.54 in the same period of 2023[21]. - Operating profit for the first nine months of 2024 was -¥16,087,529.89, compared to -¥6,109,030.26 in the same period of 2023, indicating a worsening of 163.5%[22]. - Net profit for the first nine months of 2024 was -¥16,117,302.93, compared to -¥6,294,345.42 in the same period of 2023, reflecting an increase in losses of 156.5%[22]. - The total comprehensive income for the period was -¥15,048,335.49, compared to -¥5,317,980.32 in the same period last year[24]. Assets and Liabilities - Total assets as of September 30, 2024, were CNY 401,438,503.20, a decrease of 5.26% compared to the end of the previous year[3]. - The company's current assets total 69,519,860.54, a decrease from 80,413,784.74 in the previous year[15]. - The company's inventory has decreased from 30,789,663.07 to 22,978,526.59, indicating a reduction of approximately 25.5%[15]. - Fixed assets have increased significantly from 159,187,288.72 to 290,700,115.04, reflecting a growth of approximately 82.5%[15]. - Current liabilities decreased from 80.14 billion to 76.54 billion, a reduction of about 4.0%[16]. - Non-current liabilities decreased from 26.26 billion to 23.70 billion, a decrease of approximately 9.7%[16]. - Total liabilities decreased from 106.40 billion to 100.25 billion, a decline of around 5.4%[17]. - Shareholders' equity decreased from 317.31 billion to 301.19 billion, a reduction of about 5.1%[17]. Cash Flow - The net cash flow from operating activities for the first nine months of 2024 was CNY 14,062,426.82, an increase of 2,820.43% year-over-year[3]. - The net cash flow from operating activities for the first nine months of 2024 was ¥14,062,426.82, compared to a negative cash flow of ¥516,918.53 in the same period of 2023[26]. - Total cash inflow from operating activities was ¥103,535,818.11, down 16.3% from ¥123,743,294.55 in the previous year[25]. - The net cash flow from investing activities was -¥6,886,536.20, significantly improved from -¥33,349,200.10 in the same period last year[26]. - Cash inflow from financing activities decreased to ¥65,000,000.00 from ¥113,000,000.00 year-over-year, a decline of 42.5%[26]. - The total cash outflow from operating activities was ¥89,473,391.29, down from ¥124,260,213.08 year-over-year[25]. - The company’s cash flow from financing activities resulted in a net outflow of -¥7,127,260.05, compared to a net inflow of ¥12,861,343.35 in the previous year[26]. Shareholder Information - The total number of ordinary shares at the end of the reporting period is 111,360,400, with 62.36% being freely tradable shares[8]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[9]. - The number of shareholders holding more than 5% of shares has increased to 10, with a total holding of 72,785,678 shares, representing 65.36% of total shares[9]. Expenses - Management expenses increased by 29.71% to CNY 20,376,309.51, primarily due to depreciation costs from new production lines[4]. - Research and development expenses for the first nine months of 2024 were ¥6,643,893.80, a decrease of 14.3% from ¥7,749,700.05 in the same period of 2023[21]. - Sales expenses decreased to ¥11,352,942.59 from ¥14,164,333.56, a reduction of 19.7%[21]. - Tax expenses increased to ¥1,209,822.09 from ¥810,219.72, an increase of 49.2%[21]. - Other income increased to ¥4,305,456.31 from ¥3,955,979.67, an increase of 8.8%[21]. Other Information - The company has no major litigation or arbitration matters reported during the period[11]. - The company has engaged in related party transactions, with a total expected amount of 213,000,000, of which 29,000,000 has been executed[12]. - The company has pledged assets totaling 93,966,865.82, which accounts for 23.41% of total assets[14]. - The company has fulfilled all disclosed commitments without any overdue obligations during the reporting period[13]. - Non-recurring gains and losses totaled CNY 4,230,542.76, reflecting various adjustments and government subsidies[6].

上海市锦天城律师事务所 关于山西大禹生物工程股份有限公司 2024 年第二次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：（86）21-20511000 传真：（86）21-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于山西大禹生物工程股份有限公司 2024 年第二次临时股东大会的法律意见书 经本所律师核查，本次股东大会召集人资格合法、有效，本次股东大会召集、 召开程序符合《公司法》《上市公司股东大会规则》等法律、法规和其他规范性 文件以及《公司章程》的有关规定。 致：山西大禹生物工程股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受山西大禹生物工程股份 有限公司（以下简称"公司"）委托，就公司召开 2024 年第二次临时股东大会 （以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《上市公司股东大会规则》等法律、法规和其他规范 性文件以及《山西大禹生物工程股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-047 山西大禹生物工程股份有限公司 2024 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 6.召开情况合法、合规、合章程性说明： 本次股东大会会议的召集、召开、议案审议程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 22 人，持有表决权的股份总数 62,510,538 股，占公司有表决权股份总数的 56.4170%。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 9 月 12 日 2.会议召开地点：大禹生物三楼会议室 3.会议召开方式：现场投票和网络投票相结合方式 4.会议召集人：董事会 5.会议主持人：董事长闫和平先生 其中通过网络投票参与本次股东大会的股东共 6 人，持有表决权的股份总数 4,817,771 股，占公司有表决权股份总数的 4.3481%。 （三）公司董事、监事、高级管理人 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 57,253,634.38, a decrease of 17.32% compared to CNY 69,247,737.67 in the same period last year[13]. - The net profit attributable to shareholders was a loss of CNY 10,450,290.31, representing a decline of 72.24% from a loss of CNY 6,067,336.80 in the previous year[13]. - The gross profit margin decreased to 23.79% from 26.00% year-on-year[13]. - The company reported a basic earnings per share of -0.09, down from -0.05, reflecting an 80.00% decrease[13]. - The company reported a net loss due to a decline in sales of high-margin mixed feed additives, with overall gross margin decreasing significantly[38]. - The company reported a total of 10,000,000.00 yuan in loans for working capital, with a balance of 6,000,000.00 yuan as of the reporting date[46]. - The company reported a total comprehensive income for the first half of 2024 was -9,586,883.53 yuan, compared to -5,208,248.31 yuan in the first half of 2023, indicating a decline of about 84.5%[65]. - The total consolidated profit for the current year is -10,450,290.31, compared to -6,067,336.80 in the previous year, indicating a significant loss increase[188]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 414,826,190.03, down 2.10% from CNY 423,712,742.87 at the end of the previous year[14]. - The total liabilities increased by 1.47% to CNY 107,967,973.45 from CNY 106,404,235.98[14]. - The company's total equity attributable to shareholders decreased by 3.29% to CNY 306,858,216.58 from CNY 317,308,506.89[14]. - The total assets amounted to 414.83 million yuan, a decrease of 2.10% compared to the end of the previous year[21]. - The total liabilities increased from ¥80,140,070.27 to ¥83,411,307.78, an increase of approximately 3.4%[57]. - The total equity attributable to shareholders at the end of the current period is 315,017,636.97 CNY, a decrease of 9,586,883.53 CNY compared to the previous period[76]. Cash Flow - The company's net cash flow from operating activities was CNY 5,759,853.11, an increase of 143.48% compared to CNY 2,365,660.95 in the same period last year[16]. - The cash flow from financing activities decreased by 18.26% to CNY 2,754,238.85 from CNY 3,369,378.31 in the previous year[34]. - The net cash flow from operating activities increased to 5,759,853.11 yuan, compared to 2,365,660.95 yuan in the first half of 2023[66]. - The cash and cash equivalents at the end of the period amount to 22,757,512.26, compared to 19,800,900.30 at the beginning of the period, reflecting a net increase of 2,956,611.96[189]. Expenses - Sales expenses have decreased by 30.94% to CNY 6,852,585.24, compared to CNY 9,922,636.49 in the same period last year[25]. - The company's management expenses increased by 25.27% to CNY 12,910,864.22, primarily due to depreciation costs from new production lines[25]. - The company's financial expenses increased to CNY 1,181,712.74 in the first half of 2024 from 680,185.14 in the same period of 2023, an increase of approximately 73.6%[65]. - The total operating costs for the first half of 2024 were CNY 70,116,632.08, down from CNY 78,135,397.06 in the first half of 2023, reflecting a reduction of 10.3%[62]. Research and Development - The company has been recognized as a high-tech enterprise and a provincial-level "specialized, refined, distinctive, and innovative" enterprise[20]. - Research and development expenses for the first half of 2024 were CNY 4,480,393.69, down from CNY 5,210,733.62 in the same period of 2023, a decrease of 14.0%[62]. - The company plans to enhance the sales and promotion of feed additives, aiming to improve profitability and optimize the existing sales team[39]. Market Conditions - The overall production of industrial feed in China decreased by 4.1% year-on-year in the first half of 2024[22]. - User data indicates a significant decline in pig inventory due to the African swine fever and market conditions, leading to reduced feed sales[32]. - The company is facing risks from major animal epidemics and natural disasters, which could impact the demand for feed and additives[40]. Shareholder Information - The actual controllers of the company hold 49.94% of the shares, which may influence major decisions and potentially affect minority shareholders' interests[43]. - The largest shareholder, Yan Heping, holds 53,246,000 shares, representing 47.81% of the total shares[50]. - The total number of shares held by the top ten shareholders is 81,209,600, accounting for 72.92% of the total shares[50]. Governance and Compliance - The company has established a governance structure to ensure decision-making processes are transparent and protect the interests of minority shareholders[43]. - There have been no significant changes in major risks during the reporting period[43]. - The company confirmed its ability to continue operations for at least 12 months from the reporting date, with no significant issues affecting its ongoing viability[85]. Credit and Risk Management - The company manages credit risk through policies that assess customer creditworthiness based on financial status and market conditions, ensuring overall credit risk remains controllable[197]. - The company has established measures to control credit risk exposure related to accounts receivable and other receivables[197]. - The company does not perceive significant credit risk from its bank deposits, which are primarily held in state-owned and large listed banks[196].

国投证券股份有限公司 关于山西大禹生物工程股份有限公司 部分募投项目用途变更的核查意见 截至2024年6月30日，公司募集资金使用情况如下： | 序号 | 募集资金用途 | 拟投入募集资 | 募集资金累计 | 投资进度 | | --- | --- | --- | --- | --- | | | | 金总额 | 投入金额 | | | 1 | 微生态制剂产业化项目 | 102,455,000.00 | 102,574,677.63 | 100.12% | | 2 | 营销服务中心建设项目 | 29,435,471.69 | 16,623,655.00 | 56.47% | 单位：元 1 一、募集资金基本情况 公司向不特定合格投资者公开发行股票并在北京证券交易所上市申请于 2022年3月25日经北京证券交易所上市委员会审核同意，并于2022年4月19日经 中国证券监督管理委员会同意注册（证监许可〔2022〕826号）。 公司本次发行价格为10元/股，发行股数为15,000,000股，实际募集资金总 额为150,000,000.00元，扣除发行费用18,109,528.31元（不含税），实际募集资 金净额为131,8 ...

一、募集资金基本情况 公司向不特定合格投资者公开发行股票并在北京证券交易所上市申请已于 2022 年 3 月 25 日经北京证券交易所上市委员会审核同意，并于 2022 年 4 月 19 日经中国证券监督管理委员会注册同意（证监许可〔2022〕826 号）。公司本 次发行价格为 10 元/股，发行股数为 15,000,000 股，实际募集资金总额为 150,000,000.00 元，扣除发行费用 18,109,528.31 元（不含税），实际募集资金净 额为 131,890,471.69 元。截至 2022 年 5 月 10 日，上述募集资金已全部到账， 并由信永中和会计师事务所（特殊普通合伙）出具了 XYZH/2022SYAA10105《验 资报告》。 截至 2024 年 6 月 30 日，公司累计使用募集资金人民币 119,198,332.63 元， 其中微生态制剂产业化项目使用募集资金 102,574,677.63 元，营销服务中心建设 项目使用募集资金 16,623,655.00 元。募集资金均用于公司已披露的募集资金项 目。 | 户名 | 开户行 | 账号 | 余额 | | --- | --- | ...

本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 5.会议主持人：赵一霖 6.召开情况合法、合规、合章程性说明： 证券代码：871970 证券简称：大禹生物 公告编号：2024-040 山西大禹生物工程股份有限公司 第三届监事会第十二次会议决议公告 本次会议的召开符合《中华人民共和国公司法》、《公司章程》和《监事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《关于公司 2024 年半年度报告及摘要》议案 1.议案内容： 根据《公司法》《北京证券交易所股票上市规则（试行）》等法律法规及《公 司章程》等公司内部治理文件的规定，依据公司的实际情况，公司编制了《2024 1.会议召开时间：2024 年 8 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场 4.发出监事会会议通知的时间和方式：2024 年 8 月 23 日 以通讯方式发出 年半年度报 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-046 山西大禹生物工程股份有限公司 关于召开 2024 年第二次临时股东大会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 本次会议为 2024 年第二次临时股东大会。 （二）召集人 本次股东大会的召集人为董事会。 （三）会议召开的合法性、合规性 本次股东大会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东只能选择现场投票、网络投票中的一种方式，如果同一表决 权出现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 一、会议召开基本情况 （一）股东大会届次 1、现场会议召开时间：2024 年 9 月 12 日 15:00。 2、网络投票起止时间：2024 年 9 月 11 日 15:00—2024 年 9 月 12 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简称"中国结 算 ...

证券代码：871970 证券简称：大禹生物 公告编号：2024-039 山西大禹生物工程股份有限公司 第三届董事会第十五次会议决议公告 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 8 月 26 日 2.会议召开地点：公司会议室 3.会议召开方式：现场及通讯 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 4.发出董事会会议通知的时间和方式：2024 年 8 月 23 日以通讯方式发出 5.会议主持人：闫和平 6.会议列席人员：监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召开符合《中华人民共和国公司法》《公司章程》和《董事会议 事规则》的有关规定，所作决议合法有效。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事吴秋生因工作原因以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于公司 2024 年半年度报告及摘要的议案》 1.议案内容： 根据《公司法》《北京证券交易所股票上市规则（试行）》等法律法规及《公 司 ...